Alexithymia has been linked to cardiovascular disease. The aim was to explore whether the immuno-inflammatory variables galectin-3 binding protein (Gal3BP), soluble (s)CD163 and galectin-3 were independently associated with alexithymia, while controlling for known risk factors for cardiovascular disease, such as depression, anxiety, impaired glycemic control, obesity, smoking, and physical inactivity in patients with type 1 diabetes (T1D). Cross-sectional design. The participants were consecutively recruited from one diabetes out-patient clinic. Alexithymia, depression and anxiety were assessed by self-report instruments. Blood samples, anthropometrics, and blood pressure were collected, supplemented with data from electronic health records. High Gal3BP was defined as ≥3.3 μg/ml, high sCD163 as ≥0.6 μg/ml, high galectin-3 as ≥2.6 ng/ml, impaired glycemic control as HbA1c >70 mmol/mol (>8.6%) and abdominal obesity as waist circumference ≥ 1.02 m for men and ≥ 0.88 m for women. Two hundred and ninety two patients participated (men 56%, aged 18-59 years, alexithymia prevalence 15%). Patients with alexithymia had higher prevalence of depression (34 vs. 6%, < 0.001), anxiety (61 vs. 30%, < 0.001), high Gal3BP levels (39 vs. 17%, = 0.004), high HbA1c levels (46 vs. 24%, = 0.006), and abdominal obesity (29 vs. 15%, = 0.045). Depression [adjusted odds ratio (AOR) 6.5 < 0.001], high Gal3BP levels (AOR 2.4, = 0.035), and age (AOR 0.96, = 0.027) were independently associated with alexithymia. Abdominal obesity (AOR 4.0, < 0.001), high Gal3BP levels (AOR 2.8, = 0.002), and depression (AOR 2.9, = 0.014) were associated with high HbA1c. Abdominal obesity and anxiety were associated [Crude odds ratio (COR) 2.4, = 0.006]. T1D patients with alexithymia had higher prevalence of high Gal3BP levels, depression, impaired glycemic control, anxiety, and abdominal obesity, which are known risk factors for cardiovascular disease. Only high Gal3BP levels, depression, and younger age were independently associated with alexithymia in adult patients with T1D.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144300 | PMC |
| http://dx.doi.org/10.3389/fpsyt.2021.672931 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of Inflammation/Immune-, Acute Phase-, Extracellular Matrix-, Adhesion-, and Serine Protease-Related Proteins in the Amniotic Fluid of Women With Early Preterm Prelabor Rupture of Membranes.
Am J Reprod Immunol
August 2024
Departments of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Article Synopsis
- The study investigates the link between specific proteins in amniotic fluid and complications in pregnant women with early preterm prelabor rupture of membranes (PPROM), focusing on microbial invasion and inflammation in the amniotic cavity.
- 111 women with PPROM had their amniotic fluid tested for various proteins to see if their concentrations correlated with conditions like microbial invasion or the risk of premature delivery.
- Results showed that higher levels of certain proteins (such as IL-8 and MMP-8) are connected to increased risks of early labor and serious neonatal outcomes, suggesting that these proteins play crucial roles in the immune response to infection during pregnancy.
Diagnostic Value of Serum Galectin-3 Binding Protein Level in Patients with Pulmonary Arterial Hypertension.
Curr Vasc Pharmacol
March 2024
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China National Clinical Research Center for Interventional Medicine, Shanghai, China.
Background: Pulmonary arterial hypertension (PAH) still lacks effective biomarkers to assist in its diagnosis and prognosis. Galectin-3 binding protein (Gal-3BP) plays a role in immune and inflammatory diseases.
Objective: This study aimed to evaluate Gal-3BP as a prognostic and predictive factor in patients with PAH.
Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
Mol Pharm
June 2023
Department of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States.
Galectin-3 binding protein (Gal-3BP) is a glycoprotein that is overexpressed and secreted by several cancers and has been implicated as a marker of both tumor progression and poor prognosis in melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and breast cancer. The expression of Gal-3BP by a variety of neoplasms makes it an enticing target for both diagnostics and therapeutics, including immuno-positron emission tomography (immunoPET) probes and antibody-drug conjugates (ADCs). Herein, we report the development, characterization, and evaluation of a pair of Gal-3BP-targeting radioimmunoconjugates for Zr-immunoPET.
View Article and Find Full Text PDFAssociation of Serum Galectin-3-Binding Protein and Metabolic Syndrome in a Chinese Adult Population.
Front Endocrinol (Lausanne)
February 2022
Institute of Health Sciences, China Medical University, Shenyang, China.
Background: Galectin-3-binding protein (GAL-3BP) is a ubiquitous and multifunctional secreted glycoprotein, which functions in innate immunity and has been highlighted as a potential mediator of adipose inflammation in obesity. In this study, we aimed to identify whether GAL-3BP is a novel biological marker for metabolic syndrome (MetS).
Methods: The biochemical and anthropometric variables of the 570 participants in this study were evaluated using standard procedures.
Galectin-3 Binding Protein, Depression, and Younger Age Were Independently Associated With Alexithymia in Adult Patients With Type 1 Diabetes.
Front Psychiatry
May 2021
Diabetes Research Laboratory, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
Alexithymia has been linked to cardiovascular disease. The aim was to explore whether the immuno-inflammatory variables galectin-3 binding protein (Gal3BP), soluble (s)CD163 and galectin-3 were independently associated with alexithymia, while controlling for known risk factors for cardiovascular disease, such as depression, anxiety, impaired glycemic control, obesity, smoking, and physical inactivity in patients with type 1 diabetes (T1D). Cross-sectional design.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!